Latest News

First investigational drug therapy for liver disease NASH awaiting FDA approval

Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy, but this may soon change. A large Phase III clinical trial designed in collaboration with Virginia Commonwealth University is the first to demonstrate the safety and effectiveness of an oral medication to treat the disease.

Source link

Related posts

Opinion: A simple bureaucratic organ donation fix will save thousands of lives


Is Your Smartphone Making You Fat?


Biomarkers help tailor diuretic use in acute heart failure patients


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy